Berberine (CAS 2086-83-1): AMPK Activator & LDLR Upregulator for Metabolic and Inflammation Research

Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid extracted primarily from Cortex Phellodendri Chinensis with a molecular weight of 336.36 g/mol and the formula C₂₀H₁₈NO₄ (APExBIO). It activates AMP-activated protein kinase (AMPK), leading to modulation of glucose and lipid metabolism and upregulation of LDL receptor (LDLR) expression in hepatoma cells at concentrations up to 15 μg/mL. Berberine exhibits anti-inflammatory and antimicrobial activities, and is used extensively in models of diabetes, obesity, and cardiovascular disease. Its solubility profile—insoluble in water/ethanol, ≥14.95 mg/mL in DMSO—dictates its handling in laboratory settings. Recent studies link Berberine to modulation of the NLRP3 inflammasome, highlighting its relevance in acute kidney injury (AKI) and inflammation research (Li et al., 2025).

Biological Rationale

Berberine is a naturally occurring isoquinoline alkaloid recognized for its broad pharmacological profile. Its core activity involves activation of AMPK, a central regulator of cellular energy homeostasis (APExBIO). This activation influences glucose uptake, lipid oxidation, and cholesterol metabolism. Additionally, Berberine modulates inflammatory signaling, including the NLRP3 inflammasome pathway, which is implicated in sterile inflammation and tissue injury (Li et al., 2025). As such, Berberine is positioned at the intersection of metabolic regulation and inflammation control, making it integral to research on diabetes, cardiovascular disease, obesity, and acute kidney injury. For further analysis of its role in NLRP3 modulation, see this article, which focuses on inflammasome-targeted effects; the present dossier extends these mechanisms to translational metabolic models.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine acts primarily through the activation of AMP-activated protein kinase (AMPK). AMPK upregulation leads to downstream effects, including:

• Enhanced glucose uptake and insulin sensitivity via GLUT4 translocation.
• Suppression of hepatic gluconeogenesis and fatty acid synthesis.
• Upregulation of LDL receptor (LDLR) expression at both mRNA and protein levels in hepatoma cell lines (HepG2, Bel-7402), with maximal effects observed at 15 μg/mL.
• Inhibition of proinflammatory cytokine production through modulation of the NLRP3 inflammasome and STING signaling pathways (Li et al., 2025).

Berberine is not readily soluble in water or ethanol but achieves solubility of ≥14.95 mg/mL in DMSO, which is critical for in vitro and in vivo dosing. The molecule also demonstrates indirect regulation of mitochondrial function and oxidative stress responses (Related Article); this piece extends the mechanistic focus to include updated inflammasome and metabolic benchmarks.

Evidence & Benchmarks

• Berberine upregulates LDLR mRNA and protein expression in HepG2 and Bel-7402 cells in a dose-dependent manner, maximal at 15 μg/mL (APExBIO).
• In hyperlipidemic golden hamsters, oral Berberine at 50 or 100 mg/kg/day for 10 days significantly lowers serum total cholesterol and LDL cholesterol, with increased hepatic LDLR expression (APExBIO).
• Berberine activates AMPK signaling, leading to improved metabolic parameters in models of diabetes and obesity (Balaglitazone.com).
• Berberine modulates the NLRP3 inflammasome, reducing inflammation in models of acute kidney injury and metabolic disease (Li et al., 2025).
• Berberine is insoluble in water/ethanol, but soluble in DMSO at ≥14.95 mg/mL; warming to 37°C or ultrasonic shaking improves dissolution (APExBIO).

Applications, Limits & Misconceptions

Berberine is widely applied in metabolic disease research, including:

• Diabetes models: Used to improve glycemic control and insulin sensitivity through AMPK activation.
• Obesity research: Reduces body weight gain and adiposity in animal models.
• Cardiovascular studies: Lowers serum cholesterol and modulates LDLR expression.
• Inflammation and AKI: Modulates NLRP3 inflammasome activity, reducing tissue injury (Li et al., 2025).

To integrate Berberine into workflows, see this resource for advanced protocols and troubleshooting; the present article adds new data on LDLR and NLRP3 axes.

Common Pitfalls or Misconceptions

• Berberine is not bioavailable orally in its unmodified form; in vivo efficacy depends on formulation and dosing (APExBIO).
• Berberine is insoluble in aqueous buffers; improper dissolution may lead to precipitation and inaccurate dosing.
• Not all anti-inflammatory effects are AMPK-dependent; NLRP3 modulation can occur via additional pathways (Li et al., 2025).
• Long-term storage of Berberine solutions is not recommended; use freshly prepared stocks below -20°C.
• Berberine is not a substitute for statins or established anti-diabetic drugs in clinical protocols; its use is research-only.

Workflow Integration & Parameters

Berberine is typically supplied as a solid, stored at -20°C, sealed and protected from moisture and heat. For laboratory use:

• Dissolve in DMSO (≥14.95 mg/mL); heat to 37°C or use ultrasonic agitation to enhance dissolution.
• Prepare only as much solution as required for immediate use; avoid long-term storage of working stocks.
• In cellular studies, 15 μg/mL is the maximal concentration for upregulating LDLR in hepatoma cells.
• In animal models, effective dosing is 50–100 mg/kg/day orally for 10 days in metabolic studies.

For product specifications and ordering, see Berberine (CAS 2086-83-1) from APExBIO. This article clarifies concentration benchmarks and procedural details beyond previous reviews, which focused on broader systems-level perspectives.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a validated AMPK activator and LDLR upregulator with robust applications in metabolic and inflammation research. Its dual action on metabolic and inflammatory pathways, including NLRP3 inflammasome modulation, provides unique translational value. Researchers should consider its handling constraints and dosing parameters. For comprehensive application in metabolic disease models, APExBIO provides high-purity Berberine for reproducible results (product page). Ongoing research continues to elucidate its mechanisms, especially in the context of acute kidney injury and sterile inflammation (Li et al., 2025).